TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26219195

Group type: EXPERIMENTAL
Intervention: Curcumin (CRM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-Metronidazole (CHX-MTZ)
Number of subjects: 60
Study: 25377585

Group type: EXPERIMENTAL
Intervention: 3M ESPE Clinpro XT Varnish (n=35)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Multifluorid (n=37)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Gluftored (n=23)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 136
Study: 22959103

Group type: EXPERIMENTAL
Intervention: L‐CRA (Laser-induced chorioretinal venous anastomosis)
Number of subjects: 55
Study: 19179968

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b monotherapy (1.5 micro g/kg/wk for 48 weeks)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b monotherapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Combination therapy (pegylated interferon alfa-2b + lamivudine 100 mg/d)
Number of subjects: 126
Study: 17401588

Group type: EXPERIMENTAL
Intervention: Non‐self‐tapping Ankylos implants
Number of subjects: 263

Group type: COMPARATOR
Intervention: Self‐tapping Camlog implants
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Both implant systems
Number of subjects: 263
Study: 15257187

Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg) and Indapamide (0.625 mg)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide
Number of subjects: 146
Study: 11219481

Group type: EXPERIMENTAL
Intervention: Extended-release clarithromycin (two 500-mg tablets once daily for 7 days)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (one 875-mg tablet twice daily for 10 days)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Extended-release clarithromycin
Number of subjects: 287

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 287
Study: 9510706

Group type: EXPERIMENTAL
Intervention: Structured patient‐centred education programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual ad hoc information
Number of subjects: 40
Study: 8287747

Group type: EXPERIMENTAL
Intervention: C-reactive protein level higher than 2.5 mg/dl (Group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: C-reactive protein level lower than 2.5 mg/dl (Group B)
Number of subjects: 56

Group type: COMPARATOR
Intervention: C-reactive protein level in nonspecific abdominal pain (Group C)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Diseases other than acute appendicitis (Group D)
Number of subjects: 56
Study: 3174047

Group type: EXPERIMENTAL
Intervention: disk-repositioning onlays
Number of subjects: 63

Group type: COMPARATOR
Intervention: flat occlusal splint
Number of subjects: 63

Group type: COMPARATOR
Intervention: untreated controls
Number of subjects: 63
Study: 31630923

Group type: EXPERIMENTAL
Intervention: Nonfaith-based abstinence-only intervention
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Faith-based abstinence-only intervention
Number of subjects: 613

Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 613
Study: 29181880

Group type: EXPERIMENTAL
Intervention: Titanium abutment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Zirconia abutment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gold alloy abutment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (Titanium)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (Zirconia)
Number of subjects: 15
Study: 27234409

Group type: EXPERIMENTAL
Intervention: Talactoferrin (TLf) administered twice daily by gastric gavage from day 1-28 of life
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Talactoferrin (TLf)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (excipient)
Number of subjects: 21
Study: 25582960

Group type: EXPERIMENTAL
Intervention: 16-week home-based resistance training program
Number of subjects: 26
Study: 23316290

Group type: EXPERIMENTAL
Intervention: Bromocriptine-QR (1.6 to 4.8 mg/day)
Number of subjects: 3070

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3070
Study: 20059527

Group type: EXPERIMENTAL
Intervention: THP-COP
Number of subjects: 53
Study: 18713890

Group type: EXPERIMENTAL
Intervention: 30% oxygen with air (G0)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 50% N(2)O with oxygen (G50)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 70% N(2)O with oxygen (G70)
Number of subjects: 137
Study: 16897910

Group type: EXPERIMENTAL
Intervention: Computer-administered survey
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 334

Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire
Number of subjects: 334
Study: 12942855

Group type: EXPERIMENTAL
Intervention: Continuous trajectory of psychotropic drug consumption (uninterrupted consumption during the 5-year follow-up)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Occasional trajectory of psychotropic drug consumption (interruption of consumption for at least 1 month)
Number of subjects: 286
Study: 10321394

Group type: EXPERIMENTAL
Intervention: Progressive exercise programme
Number of subjects: 27

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 27
Study: 8911887

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg) with grapefruit juice (250 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amlodipine (5 mg) with water
Number of subjects: 12
Study: 1887983

Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 20
Study: 6961737

Group type: EXPERIMENTAL
Intervention: Human milk (1.6 g/100 kcal)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Formula 1 (2.3 g/100 kcal)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Formula 2 (3.0 g/100 kcal)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (Human milk)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study: 31499415

Group type: EXPERIMENTAL
Intervention: sildenafil 25 mg three times daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study: 30646105

Group type: EXPERIMENTAL
Intervention: Stimulants
Number of subjects: 66406

Group type: COMPARATOR
Intervention: No stimulants
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Long-term concurrent stimulant-opioid use
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Age 30s
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Age 40s
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Age 50s
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Non-Hispanic white
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Living in the southern United States
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Substance abuse disorder
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Anxiety disorder
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease
Number of subjects: 66406

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease
Number of subjects: 66406
Study: 27323793

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24532143

Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg daily for 3 days after surgery (intervention group, n = 59)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No haloperidol (control group, n = 60)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg daily for 3 days after surgery (intervention group)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No haloperidol (control group)
Number of subjects: 119
Study: 22188327

Group type: EXPERIMENTAL
Intervention: Ultrasonic tips
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Masserann kit
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 39
Study: 20056480

Group type: EXPERIMENTAL
Intervention: Emtricitabine once-a-week (A)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Emtricitabine once-a-day (B)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lamivudine once-a-day (C)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Emtricitabine once-a-day (B) and Lamivudine once-a-day (C)
Number of subjects: 38
Study: 17236758

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 mcg b.i.d.
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 16167253

Group type: EXPERIMENTAL
Intervention: Diode laser coagulation (laser group, n=46)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Hemorrhoidectomy (control group, n=40)
Number of subjects: 86
Study: 11960538

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 85) with tailored recommendations about optimizing dialysis prescriptions, expedited conversion of catheters to grafts/fistulas, and patient education.
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 85) with tailored recommendations.
Number of subjects: 169
Study: 9857880

Group type: EXPERIMENTAL
Intervention: Continuous transdermal GTN, 0.6 mg/h
Number of subjects: 15
Study: 8559862

Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia with neutral phrases (color blue or yellow combined with objects ball or kite)
Number of subjects: 36
Study: 1977646

Group type: EXPERIMENTAL
Intervention: Filshie clip
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pomeroy method
Number of subjects: 200
Study: 344084

Group type: EXPERIMENTAL
Intervention: Trancopal (two tablets at night for two weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (two tablets at night for two weeks)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Trancopal
Number of subjects: 85
Study: 31491106

Group type: EXPERIMENTAL
Intervention: Randomized compiler for Hamiltonian simulation
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Phase estimation at chemical accuracy
Number of subjects: 3
Study: 28162781

Group type: COMPARATOR
Intervention: Intra-articular corticosteroids alone
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroids plus methotrexate
Number of subjects: 207
Study: 24801567

Group type: COMPARATOR
Intervention: Middle-aged group during swing phase walking
Number of subjects: 30

Group type: COMPARATOR
Intervention: Middle-aged group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Facilitated swing-phase H-reflex group
Number of subjects: 30
Study: 23819219

Group type: EXPERIMENTAL
Intervention: Ear-apex blood-letting (5-6 blood drops/time, once daily for 3 times)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine treatment (local application of hydrochloric levofloxacin and erycin ointment, plus local warm compress)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ear-apex blood-letting
Number of subjects: 102
Study: 21480953

Group type: EXPERIMENTAL
Intervention: PPI prompt group
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: PPI prompt pharmacies
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control pharmacies
Number of subjects: 196
Study: 19861603

Group type: EXPERIMENTAL
Intervention: 3 ± 1 bites of Anopheles albimanus mosquitoes infected with P. vivax
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 6 ± 1 bites of Anopheles albimanus mosquitoes infected with P. vivax
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 9 ± 1 bites of Anopheles albimanus mosquitoes infected with P. vivax
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (1 volunteer exposed to eight mosquito bites)
Number of subjects: 18
Study: 16555151

Group type: EXPERIMENTAL
Intervention: Radical excision
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Palliative operation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Exploratory operation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Synchronous hepatic metastasis risk factors
Number of subjects: 44
Study: 14747278

Group type: EXPERIMENTAL
Intervention: Strength training (3 times per week for 6 weeks, 30 min per session)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (untrained leg)
Number of subjects: 17
Study: 11378948

Group type: EXPERIMENTAL
Intervention: Forced air warming therapy
Number of subjects: 338

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 338
Study: 9009975

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (stepped plan from 1 evening injection to multiple daily injections)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard insulin therapy (1 injection every morning)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 153
Study: 8359954

Group type: EXPERIMENTAL
Intervention: Smoking history
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 362

Group type: COMPARATOR
Intervention: Tea consumption
Number of subjects: 362

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 362
Study: 3526655

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Azathioprine‐prednisone‐antilymphocyte globulin (ALG)
Number of subjects: 56
Study: 31895032

Group type: EXPERIMENTAL
Intervention: Show-catheter (reintroduction under the CARTO 3 show-catheter image-track function)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoroscopy (reintroduction under conventional fluoroscopy)
Number of subjects: 100
Study: 29509522

Group type: EXPERIMENTAL
Intervention: DEX + lidocaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: lidocaine
Number of subjects: 8
Study: 26421957

Group type: EXPERIMENTAL
Intervention: EE/GSD patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced-GSD patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced-EE/GSD patch
Number of subjects: 0
Study: 24719397

Group type: EXPERIMENTAL
Intervention: Electrosurgical plasma coagulation (EPC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Potassium-titanyl-phosphate (KTP) laser photocoagulation
Number of subjects: 11
Study: 23011435

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TAMAS)
Number of subjects: 30
Study: 20351596

Group type: EXPERIMENTAL
Intervention: LOW-glycogen training
Number of subjects: 14

Group type: COMPARATOR
Intervention: HIGH-glycogen training
Number of subjects: 14
Study: 18515290

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team care for older people in community hospitals
Number of subjects: 490

Group type: COMPARATOR
Intervention: General hospital care
Number of subjects: 490
Study: 15623545

Group type: EXPERIMENTAL
Intervention: Left atrial linear cryoablation (groups U and 7)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) (group PV)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Complete 7 lesion (EAM validated)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Complete PVI (EAM validated)
Number of subjects: 105
Study: 12895218

Group type: EXPERIMENTAL
Intervention: Loxiglumide (50 mg i.v.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hyoscine‐N‐butyl bromide (20 mg i.v.)
Number of subjects: 14
Study: 11127253

Group type: EXPERIMENTAL
Intervention: Ivermectin (150-200 micrograms/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Ivermectin and Albendazole (400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study: 9557072

Group type: COMPARATOR
Intervention: Increased urine cathepsin B activity (10.58 +/- 8.73 pmol AMC/mg creatinine/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased urine collagenase activity (8.59 +/- 4.26 pmol AMC/mg creatinine/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased urine excretion of fibronectin (214 +/- 335 ng/mg creatinine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increased urine excretion of TGF-beta 1 (283.55 +/- 248.13 pg/ml)
Number of subjects: 0
Study: 8317720

Group type: EXPERIMENTAL
Intervention: 1% etidocaine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 160
Study: 2941573

Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin, an antagonist of S2-serotonergic receptors
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 28937450

Group type: EXPERIMENTAL
Intervention: 1-session intervention (combined didactics and hands-on approach focused on technology-specific parenting)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 39
Study: 26446770

Group type: EXPERIMENTAL
Intervention: Morning administration of ONO-5334 150 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Evening administration of ONO-5334 150 mg
Number of subjects: 14
Study: 24395109

Group type: EXPERIMENTAL
Intervention: Central HER2 testing by Mayo Clinic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central ER testing by Mayo Clinic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAKO ER cocktail retesting at Mayo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual antibody ER assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single antibody ER assay
Number of subjects: 0
Study: 23477461

Group type: EXPERIMENTAL
Intervention: Trunk-targeted intervention using vibration
Number of subjects: 27
Study: 20579537

Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR) guided intervention
Number of subjects: 509

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: FFR measurement
Number of subjects: 509

Group type: COMPARATOR
Intervention: Angiographic assessment
Number of subjects: 509
Study: 18258621

Group type: EXPERIMENTAL
Intervention: Berry consumption
Number of subjects: 72
Study: 16504369

Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 742

Group type: COMPARATOR
Intervention: Ritodrine, Terbutaline, Salbutamol
Number of subjects: 742
Study: 14519486

Group type: EXPERIMENTAL
Intervention: 1% nitroprusside‐based gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study: 10958816

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (specific amino acids not detailed)
Number of subjects: 0
Study: 8639310

Group type: EXPERIMENTAL
Intervention: OND/CS
Number of subjects: 109

Group type: COMPARATOR
Intervention: MCP/CS
Number of subjects: 109
Study: 28928026

Group type: EXPERIMENTAL
Intervention: Work and MS (7 module resource accessed via email over a 4 week period)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Waitlist control (n=50)
Number of subjects: 95
Study: 27030614

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 153
Study: 24485216

Group type: EXPERIMENTAL
Intervention: Yearly intravenous zoledronate (ZOL)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 110
Study: 23554472

Group type: EXPERIMENTAL
Intervention: Nicotine (Nicorette gum)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21115766

Group type: EXPERIMENTAL
Intervention: Soya-yogurt snack taken prior to breakfast
Number of subjects: 10

Group type: COMPARATOR
Intervention: Breakfast taken only (control)
Number of subjects: 10
Study: 18557456

Group type: EXPERIMENTAL
Intervention: Cu-Safe 300
Number of subjects: 110

Group type: COMPARATOR
Intervention: T380A
Number of subjects: 110
Study: 16386181

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 40
Study: 12021623

Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Phenytoin group (n = 9 patients treated with 3‐4 mg/kg/d sodium phenytoin)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Carbamazepine group (n = 9 patients treated with 10‐20 mg/kg/d carbamazepine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Phenobarbital group (n = 5 patients treated with 1.5‐4.5 mg/kg/d phenobarbital)
Number of subjects: 32
Study: 10397656

Group type: EXPERIMENTAL
Intervention: Fascia flap technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no fascia flap)
Number of subjects: 32
Study: 8672906

Group type: EXPERIMENTAL
Intervention: Ethanol 2% added to the distension medium during hysteroscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative ethanol monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ethanol added)
Number of subjects: 0
Study: 2288512

Group type: EXPERIMENTAL
Intervention: Nitrendipine, 20 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6792916

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 30638426

Group type: EXPERIMENTAL
Intervention: Tai Chi (n=26)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Yoga (n=25)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stretching (n=19)
Number of subjects: 70
Study: 28934784

Group type: EXPERIMENTAL
Intervention: Double Injection (DI) group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single Injection (SI) group
Number of subjects: 36
Study: 25432103

Group type: EXPERIMENTAL
Intervention: Group II (abnormal diastolic function)
Number of subjects: 2